Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

SAB Biotherapeutics, Inc.

CIK 1833214 SABS·Biological Products · All EDGAR filings ↗

Material weakness Filing comparison

SAB Biotherapeutics, Inc. reported internal control effective again after a material weakness

Material weakness in internal control → Internal control reported effective

The weakness was first reported on 2024-03-29 — 710 days and 2 annual reports before this one.

Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have conducted an evaluation of the effectiveness of our internal control over financial reporting based on the COSO framework. Based on evaluation under these criteria, management determined that our internal control over financial reporting was effective as of December 31, 2025. Changes in Internal Control Over Financial Reporting There were no changes in our internal control…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-03-31
Prior form
10-K
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
No
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
2
Weakness days reported
710
Weakness first reported
2024-03-29
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗

Going concern Filing comparison

SAB Biotherapeutics, Inc.'s going-concern disclosure changed

Substantial doubt about ability to continue as a going concern → Risk-factor language only

… requirements, judicial decisions and guidance issued by authoritative bodies; • our ability to attract and retain key scientific, medical, commercial or management personnel; • our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; • our financial performance; • our ability to maintain our listing on The Nasdaq Capital Market; and • our ability to continue as a going concern. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the "Risk Factors" section and…
Evidence
Blank check
No
Comparable
Yes
Current state
risk_factor_only
Current state label
Risk-factor language only
Direction
eased
Located in
risk factors / forward-looking statements only
Prior filed
2025-03-31
Prior form
10-K
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗